European Commission logo
English English
CORDIS - EU research results

GRIP on MASH: Global Research Initiative for Patient Screening on MASH

Project description

Innovative platform to address MASLD burden

The disease burden and comorbidities associated with Metabolic dysfunction-associated Steatotic Liver Disease (MASLD) pose significant challenges to public health systems. Therefore, there is an urgent need to transform healthcare practices related to MASLD and alleviate the disease burden for patients. The EU-funded GRIPonMASH project aims to address this need by developing a sustainable and scalable platform for the early detection of at-risk patients developing or already diagnosed with MASLD at the primary care level. This platform, implemented across 12 European Centres of Excellence, will facilitate improved patient stratification through AI-based decision support tools utilising both existing and novel biomarkers. Additionally, it will offer personalised lifestyle advice by examining evidence-based lifestyle factors and the impact of nutritional recommendations.


GRIP on MASH will address the unmet public health need of reducing disease burden and comorbidities associated with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Together with seven medical technology, pharmaceutical and biotechnology companies, we will devise a sustainable and scalable GRIP on MASH Platform that will enable access to at-risk patients developing or having MASLD through the early detection of this condition at the primary care level. This Platform will allow A) the early detection of patients with MASLD: distributed in 12 European Centers of Excellence (CoEs), 10,000 patients at high risk of MASLD - defined as patients with type-2 diabetes mellitus, metabolic syndrome, obesity or arterial hypertension - will be screened and characterized; B) better patients’ stratification: the Platform will comprise artificial intelligence-based decision support tools that will make use of existing and novel biomarkers/biomarker combinations. Their predictive accuracy will be tested at the primary care level; there we will perform multi-OMICs analysis (proteomics, lipidomics, metabolomics, genomics, metagenomics and fluxomics) in fasted blood samples and we will explore imaging biomarkers/organ-on-a-chip to find future non-invasive diagnostic alternatives for the current standard (liver biopsies); and C) personalized lifestyle advice, by exploring evidence-based lifestyle features and the effect of nutritional recommendations: among the cohorts at the CoEs, we will use validated questionnaires to assess physical activity, diet, sleep, smoking, alcohol consumption, and perception of stress. Integrating patients’ perspectives with the participation of two patient organizations, the trustworthiness and sustainability of our GRIP on MASH Platform will be assessed by investigating potential economic, ethical and regulatory barriers to its future adoption. GRIP on MASH will change healthcare practice in MASLD and reduce the disease burden for patients.



Net EU contribution
€ 929 092,10
3584 CX Utrecht

See on map

West-Nederland Utrecht Utrecht
Activity type
Higher or Secondary Education Establishments
Total cost
€ 2 989 092,10

Participants (28)